Literature DB >> 23849993

The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities.

Julie A Moran1, Michael S Rafii, Seth M Keller, Baldev K Singh, Matthew P Janicki.   

Abstract

Adults with intellectual and developmental disabilities (I/DD) are increasingly presenting to their health care professionals with concerns related to growing older. One particularly challenging clinical question is related to the evaluation of suspected cognitive decline or dementia in older adults with I/DD, a question that most physicians feel ill-prepared to answer. The National Task Group on Intellectual Disabilities and Dementia Practices was convened to help formally address this topic, which remains largely underrepresented in the medical literature. The task group, comprising specialists who work extensively with adults with I/DD, has promulgated the following Consensus Recommendations for the Evaluation and Management of Dementia in Adults With Intellectual Disabilities as a framework for the practicing physician who seeks to approach this clinical question practically, thoughtfully, and comprehensively.
Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  I/DD; NTG; National Task Group on Intellectual Disabilities and Dementia Practices; intellectual and developmental disabilities

Mesh:

Year:  2013        PMID: 23849993     DOI: 10.1016/j.mayocp.2013.04.024

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  19 in total

Review 1.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

2.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

3.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

4.  Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.

Authors:  M S Rafii; S Zaman; B L Handen
Journal:  J Prev Alzheimers Dis       Date:  2021

Review 5.  Neurologic complications of Down syndrome: a systematic review.

Authors:  Jonathan D Santoro; Dania Pagarkar; Duong T Chu; Mattia Rosso; Kelli C Paulsen; Pat Levitt; Michael S Rafii
Journal:  J Neurol       Date:  2020-09-12       Impact factor: 6.682

6.  An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report.

Authors:  Grace E Weber; Katherine A Koenig; Maria Khrestian; Yvonne Shao; Elizabeth D Tuason; Marie Gramm; Dennis Lal; James B Leverenz; Lynn M Bekris
Journal:  J Immunol       Date:  2020-01-20       Impact factor: 5.422

7.  Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.

Authors:  Maria Carmona-Iragui; Daniel Alcolea; Isabel Barroeta; Laura Videla; Laia Muñoz; Kathyrn L Van Pelt; Frederick A Schmitt; Donita D Lightner; Lisa M Koehl; Gregory Jicha; Silvia Sacco; Clotilde Mircher; Sarah E Pape; Rosalyn Hithersay; Isabel C H Clare; Anthony J Holland; Georg Nübling; Johannes Levin; Shahid H Zaman; Andre Strydom; Anne-Sophie Rebillat; Elizabeth Head; Rafael Blesa; Alberto Lleó; Juan Fortea
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

8.  Why do we need national guidelines for adults with intellectual disability and dementia?

Authors:  Matthew P Janicki; Seth M Keller
Journal:  Alzheimers Dement (Amst)       Date:  2015-07-10

Review 9.  Further understanding the connection between Alzheimer's disease and Down syndrome.

Authors:  Heather M Snyder; Lisa J Bain; Adam M Brickman; Maria C Carrillo; Anna J Esbensen; Joaquin M Espinosa; Fabian Fernandez; Juan Fortea; Sigan L Hartley; Elizabeth Head; James Hendrix; Priya S Kishnani; Florence Lai; Patrick Lao; Cynthia Lemere; William Mobley; Elliott J Mufson; Huntington Potter; Shahid H Zaman; Ann-Charlotte Granholm; H Diana Rosas; Andre Strydom; Michelle Sie Whitten; Michael S Rafii
Journal:  Alzheimers Dement       Date:  2020-06-16       Impact factor: 16.655

10.  The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Authors:  Michael S Rafii; Hannah Wishnek; James B Brewer; Michael C Donohue; Seth Ness; William C Mobley; Paul S Aisen; Robert A Rissman
Journal:  Front Behav Neurosci       Date:  2015-09-14       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.